Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATCH-R: Continued Access to Rucaparib
NCT04676334Phase 3Completed
- Sponsor
- pharma&
- Start
- Mar 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of rucaparib in metastatic castration-resistant prostate cancer (mCRPC), ovarian cancer, epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by pharma&. Started Mar 2021; status: completed.
02
Drugs
rucaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)ovarian cancerepithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04676334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676334.